Skip to main content

Table 2 Drug-related adverse events

From: Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment

Variable

OSI (n = 85 AEs involving 48 patients)

AFA (n = 109 AEs involving 59 patients)

p valuea

 

All grades (%)

 ≥ Grade 3 (%)

All grades (%)

 ≥ Grade 3 (%)

All grades (%)

 ≥ Grade 3 (%)

Diarrhoea

24 (28.2)

8 (9.4)

47 (43.1)

25 (22.9)

0.03*

0.13

Rash

22 (25.9)

5 (5.9)

18 (16.5)

7 (6.4)

0.11

0.88

Dry skin

18 (21.2)

6 (7.1)

12 (11.0)

5 (4.6)

0.52

0.46

Paronychia

11 (12.9)

0 (0.0)

6 (5.5)

0 (0.0)

0.07

NA

Alopecia

3 (3.5)

0 (0.0)

15 (13.8)

6 (5.5)

0.02*

0.03*

Asthenia

2 (2.4)

0 (0.0)

6 (5.5)

0 (0.0)

0.27

NA

Decreased appetite

5 (5.8)

0 (0.0)

5 (4.6)

0 (0.0)

0.69

NA